Please login to the form below

Not currently logged in
Email:
Password:

PR and Med Ed news in brief

Our weekly round up of healthcare PR stories

New prescribing to be discussed

Extra prescribing powers proposed for nurses and pharmacists will be discussed at the next CIPR Health and Medical Group debate.

The event, which is targeted at healthcare communications professionals, will address the question: ìWill new prescribers make a real difference to healthcare provision?î The final line-up of speakers has now been confirmed and includes Royal College of Nursing joint prescribing adviser, Dr Molly Courtenay, the Royal Pharmaceutical Society of Great Britain director of practice and quality improvement, David Pruce, and the British Medical Association GPs committee chairman, Dr Hamish Meldrum.

The event takes place at 6pm on January 19 at the National Patient Safety Agency in central London.

Media Strategy wins APG account

Media Strategy has been awarded the public affairs account for the American Pharmaceutical Group (APG), the body that champions US pharma firms' contribution to the UK healthcare system.

The appointment marks the end of Fleishman-Hillard's 12-year handling of the account.

APG spokeswoman, Erin Huntingdon (also corporate affairs director at Lilly UK) said : ì2006 will be an important year for the UK-based pharma industry with the publication of the Government's primary care white paper, which will change the way services can be provided closer to patient homes.î

Media Strategy takes over the running of the group's secretariat, and will provide political advice on the forging of links with policymakers.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics